|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hormone/growth factor receptor
|
 |
|
Title:
|
 |
Crystal structure of the rat vitamin d receptor ligand binding domain complexed with 1,25-dihydroxyvitamin d3 and a synthetic peptide containing the nr2 box of drip 205
|
|
Structure:
|
 |
Vitamin d3 receptor. Chain: a. Fragment: ligand binding domain. Synonym: vdr, 1,25-dihydroxyvitamin d3 receptor. Engineered: yes. Mutation: yes. Peroxisome proliferator-activated receptor binding protein. Chain: c. Fragment: drip 205 nr2 box peptide.
|
|
Source:
|
 |
Rattus norvegicus. Norway rat. Organism_taxid: 10116. Gene: vdr, nr1i1. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes
|
|
Biol. unit:
|
 |
Tetramer (from
)
|
|
Resolution:
|
 |
|
2.20Å
|
R-factor:
|
0.193
|
R-free:
|
0.243
|
|
|
Authors:
|
 |
J.L.Vanhooke,M.M Benning,C.B.Bauer,J.W.Pike,H.F.Deluca
|
Key ref:
|
 |
J.L.Vanhooke
et al.
(2004).
Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide.
Biochemistry,
43,
4101-4110.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
20-Nov-03
|
Release date:
|
13-Apr-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Biochemistry
43:4101-4110
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide.
|
|
J.L.Vanhooke,
M.M.Benning,
C.B.Bauer,
J.W.Pike,
H.F.DeLuca.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
We have determined the crystal structures of the ligand binding domain (LBD) of
the rat vitamin D receptor in ternary complexes with a synthetic
LXXLL-containing peptide and the following four ligands:
1alpha,25-dihydroxyvitamin D(3);
2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD);
1alpha-hydroxy-2-methylene-19-nor-(20S)-bishomopregnacalciferol (2MbisP), and
2alpha-methyl-19-nor-1alpha,25-dihydroxyvitamin D(3) (2AM20R). The conformation
of the LBD is identical in each complex. Binding of the 2-carbon-modified
analogues does not change the positions of the amino acids in the ligand binding
site and has no effect on the interactions in the coactivator binding pocket.
The CD ring of the superpotent analogue, 2MD, is tilted within the binding site
relative to the other ligands in this study and to
(20S)-1alpha,25-dihydroxyvitamin D(3) [Tocchini-Valentini et al. (2001) Proc.
Natl. Acad. Sci. U.S.A. 98, 5491-5496]. The aliphatic side chain of 2MD follows
a different path within the binding site; nevertheless, the 25-hydroxyl group at
the end of the chain occupies the same position as that of the natural ligand,
and the hydrogen bonds with histidines 301 and 393 are maintained. 2MbisP binds
to the receptor despite the absence of the 25-hydroxyl group. A water molecule
is observed between His 301 and His 393 in this structure, and it preserves the
orientation of the histidines in the binding site. Although the alpha-chair
conformer is highly favored in solution for the A ring of 2AM20R, the crystal
structures demonstrate that this ring assumes the beta-chair conformation in all
cases, and the 1alpha-hydroxyl group is equatorial. The peptide folds as a helix
and is anchored through hydrogen bonds to a surface groove formed by helices 3,
4, and 12. Electrostatic and hydrophobic interactions between the peptide and
the LBD stabilize the active receptor conformation. This stablization appears
necessary for crystal growth.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.Cui,
C.Ma,
J.Qiu,
X.Ma,
X.Wang,
H.Chen,
and
B.Huang
(2011).
A novel interaction between insulin-like growth factor binding protein-6 and the vitamin D receptor inhibits the role of vitamin D3 in osteoblast differentiation.
|
| |
Mol Cell Endocrinol,
338,
84-92.
|
 |
|
|
|
|
 |
L.A.Plum,
and
H.F.DeLuca
(2010).
Vitamin D, disease and therapeutic opportunities.
|
| |
Nat Rev Drug Discov,
9,
941-955.
|
 |
|
|
|
|
 |
N.J.Nieves,
J.M.Ahrens,
L.A.Plum,
H.F.DeLuca,
and
M.Clagett-Dame
(2010).
Identification of a unique subset of 2-methylene-19-nor analogs of vitamin D with comedolytic activity in the rhino mouse.
|
| |
J Invest Dermatol,
130,
2359-2367.
|
 |
|
|
|
|
 |
S.Kakuda,
S.Ishizuka,
H.Eguchi,
M.T.Mizwicki,
A.W.Norman,
and
M.Takimoto-Kamimura
(2010).
Structural basis of the histidine-mediated vitamin D receptor agonistic and antagonistic mechanisms of (23S)-25-dehydro-1alpha-hydroxyvitamin D3-26,23-lactone.
|
| |
Acta Crystallogr D Biol Crystallogr,
66,
918-926.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Teichert,
L.A.Arnold,
S.Otieno,
Y.Oda,
I.Augustinaite,
T.R.Geistlinger,
R.W.Kriwacki,
R.K.Guy,
and
D.D.Bikle
(2009).
Quantification of the vitamin D receptor-coregulator interaction.
|
| |
Biochemistry,
48,
1454-1461.
|
 |
|
|
|
|
 |
A.K.Ormerod,
Z.Xing,
N.G.Pedigo,
A.Mishra,
and
D.M.Kaetzel
(2008).
The calcitriol analogue EB1089 impairs alveolarization and induces localized regions of increased fibroblast density in neonatal rat lung.
|
| |
Exp Lung Res,
34,
155-182.
|
 |
|
|
|
|
 |
G.Eelen,
N.Valle,
Y.Sato,
N.Rochel,
L.Verlinden,
P.De Clercq,
D.Moras,
R.Bouillon,
A.Muñoz,
and
A.Verstuyf
(2008).
Superagonistic fluorinated vitamin D3 analogs stabilize helix 12 of the vitamin D receptor.
|
| |
Chem Biol,
15,
1029-1034.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
H.F.DeLuca
(2008).
Evolution of our understanding of vitamin D.
|
| |
Nutr Rev,
66,
S73-S87.
|
 |
|
|
|
|
 |
N.Yoshimoto,
Y.Inaba,
S.Yamada,
M.Makishima,
M.Shimizu,
and
K.Yamamoto
(2008).
2-Methylene 19-nor-25-dehydro-1alpha-hydroxyvitamin D3 26,23-lactones: synthesis, biological activities and molecular basis of passive antagonism.
|
| |
Bioorg Med Chem,
16,
457-473.
|
 |
|
|
|
|
 |
S.Ekins,
E.J.Reschly,
L.R.Hagey,
and
M.D.Krasowski
(2008).
Evolution of pharmacologic specificity in the pregnane X receptor.
|
| |
BMC Evol Biol,
8,
103.
|
 |
|
|
|
|
 |
S.Kakuda,
K.Okada,
H.Eguchi,
K.Takenouchi,
W.Hakamata,
M.Kurihara,
and
M.Takimoto-Kamimura
(2008).
Structure of the ligand-binding domain of rat VDR in complex with the nonsecosteroidal vitamin D3 analogue YR301.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun,
64,
970-973.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
E.J.Reschly,
A.C.Bainy,
J.J.Mattos,
L.R.Hagey,
N.Bahary,
S.R.Mada,
J.Ou,
R.Venkataramanan,
and
M.D.Krasowski
(2007).
Functional evolution of the vitamin D and pregnane X receptors.
|
| |
BMC Evol Biol,
7,
222.
|
 |
|
|
|
|
 |
J.W.Pike,
M.B.Meyer,
M.Watanuki,
S.Kim,
L.A.Zella,
J.A.Fretz,
M.Yamazaki,
and
N.K.Shevde
(2007).
Perspectives on mechanisms of gene regulation by 1,25-dihydroxyvitamin D3 and its receptor.
|
| |
J Steroid Biochem Mol Biol,
103,
389-395.
|
 |
|
|
|
|
 |
L.A.Zella,
C.Y.Chang,
D.P.McDonnell,
and
J.Wesley Pike
(2007).
The vitamin D receptor interacts preferentially with DRIP205-like LxxLL motifs.
|
| |
Arch Biochem Biophys,
460,
206-212.
|
 |
|
|
|
|
 |
E.J.Reschly,
and
M.D.Krasowski
(2006).
Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.
|
| |
Curr Drug Metab,
7,
349-365.
|
 |
|
|
|
|
 |
F.Molnár,
M.Peräkylä,
and
C.Carlberg
(2006).
Vitamin D receptor agonists specifically modulate the volume of the ligand-binding pocket.
|
| |
J Biol Chem,
281,
10516-10526.
|
 |
|
|
|
|
 |
L.A.Plum,
L.A.Fitzpatrick,
X.Ma,
N.C.Binkley,
J.B.Zella,
M.Clagett-Dame,
and
H.F.DeLuca
(2006).
2MD, a new anabolic agent for osteoporosis treatment.
|
| |
Osteoporos Int,
17,
704-715.
|
 |
|
|
|
|
 |
R.Sánchez-Martínez,
A.I.Castillo,
A.Steinmeyer,
and
A.Aranda
(2006).
The retinoid X receptor ligand restores defective signalling by the vitamin D receptor.
|
| |
EMBO Rep,
7,
1030-1034.
|
 |
|
|
|
|
 |
S.Shah,
M.N.Islam,
S.Dakshanamurthy,
I.Rizvi,
M.Rao,
R.Herrell,
G.Zinser,
M.Valrance,
A.Aranda,
D.Moras,
A.Norman,
J.Welsh,
and
S.W.Byers
(2006).
The molecular basis of vitamin D receptor and beta-catenin crossregulation.
|
| |
Mol Cell,
21,
799-809.
|
 |
|
|
|
|
 |
H.Z.Ke,
H.Qi,
D.T.Crawford,
H.A.Simmons,
G.Xu,
M.Li,
L.Plum,
M.Clagett-Dame,
H.F.DeLuca,
D.D.Thompson,
and
T.A.Brown
(2005).
A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia.
|
| |
J Bone Miner Res,
20,
1742-1755.
|
 |
|
|
|
|
 |
M.D.Krasowski,
K.Yasuda,
L.R.Hagey,
and
E.G.Schuetz
(2005).
Evolutionary selection across the nuclear hormone receptor superfamily with a focus on the NR1I subfamily (vitamin D, pregnane X, and constitutive androstane receptors).
|
| |
Nucl Recept,
3,
2.
|
 |
|
|
|
|
 |
P.W.Jurutka,
P.D.Thompson,
G.K.Whitfield,
K.R.Eichhorst,
N.Hall,
C.E.Dominguez,
J.C.Hsieh,
C.A.Haussler,
and
M.R.Haussler
(2005).
Molecular and functional comparison of 1,25-dihydroxyvitamin D(3) and the novel vitamin D receptor ligand, lithocholic acid, in activating transcription of cytochrome P450 3A4.
|
| |
J Cell Biochem,
94,
917-943.
|
 |
|
|
|
|
 |
W.Sicinska,
W.M.Westler,
and
H.F.DeLuca
(2005).
NMR assignments of tryptophan residue in apo and holo LBD-rVDR.
|
| |
Proteins,
61,
461-467.
|
 |
|
|
|
|
 |
Z.Q.Fu
(2005).
Three-dimensional model-free experimental error correction of protein crystal diffraction data with free-R test.
|
| |
Acta Crystallogr D Biol Crystallogr,
61,
1643-1648.
|
 |
|
|
|
|
 |
L.A.Plum,
J.M.Prahl,
X.Ma,
R.R.Sicinski,
S.Gowlugari,
M.Clagett-Dame,
and
H.F.DeLuca
(2004).
Biologically active noncalcemic analogs of 1alpha,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl.
|
| |
Proc Natl Acad Sci U S A,
101,
6900-6904.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |